Partnering opportunity

Aptamer targeting hormone refractory prostate cancer

Summary

A German university seeks licensees for a special molecule (aptamer) that targets hormone refractory prostate cancer. The aptamer of the presented invention may be used for diagnostic or therapeutic purposes. It is easier to produce and less expensive in production than similar applications. The license agreement could include a technical cooperation regarding the generation of aptamer.

Partner sought

The university offers a license agreement that can include technical collaboration. The offer addresses companies from the pharmaceutical or biotechnology sector that are active in the treatment of prostate cancer. In the case of a license acceptance, the following tasks would be assigned to a potential partner: a. Development of diagnostic test or b. Development of an innovative biological agent into a therapeutic drug The exact tasks of the inventors in the case of an additional technical collaboration would have to be determined first. However, the inventors could contribute their special know-how in the production of aptamers.

Description

Prostate cancer is the most common cancer among men. In particular, hormone refractory prostate cancer is not curable and targeted therapies are yet not available. Hormone refractory prostate tumor cells likely metastasize to distal sites accounting for poor prognosis and survival of patients. Thus, means for early diagnosis and treatment of hormone refractory prostate cancer are desperately needed. A German university now found an aptamer that targets hormone refractory prostate cancer. Aptamers are an emerging class of molecules for developing targeted therapy approaches. They are single chain nucleic acids, folding into well-defined three-dimensional shapes based on which they recognize target structures. The inventors used an orthotopic xenograft mouse model to perform an in vivo selection in order to identify an aptamer that selectively binds to cells of a hormone refractory prostate tumor. Several rounds of selection starting from a DNA library yielded an aptamer that binds to tumor tissue in vivo and to PC3 cells in vitro. The aptamer is characterized in a PEGylation pattern that stabilizes the aptamer and prolongs plasma half-life. In this particular case, the PEGylation was already present during in vivo selection. In so-called PEGylation, biopharmaceutical active ingredients or diagnostics are chemically combined with polyethylene glycol.The aptamer of the present invention may be used for diagnostic or therapeutic purposes. In particular when coupled to a drug, the aptamer may be used in analogy to an antibody-drug-conjugate. The offer addresses companies from the pharmaceutical or biotechnology sector that are active in the treatment of prostate cancer.The university seeks licensees for this special molecule (aptamer) that targets hormone refractory prostate cancer. The university also offers a technical cooperation to licensees when it comes to the generation of aptamer.

Advantages and innovations

Compared to similar applications, this approach shows a higher affinity and selectivity of the aptamer for the tumor. Aptamers are cheaper and easier to handle than comparable antibodies. Other advantages are: - Easy to produce - High plasma half-life

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company